# Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease

> **NCT00025896** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 8 (—)

## Conditions studied

- Pompe Disease
- Glycogen Storage Disease Type II
- Acid Maltase Deficiency Disease
- Glycogenosis 2

## Interventions

- **DRUG:** recombinant human acid alpha-glucosidase (rhGAA)

## Key facts

- **NCT ID:** NCT00025896
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** —
- **Final completion:** 2002-09
- **Target enrollment:** 8 (—)
- **Last updated:** 2014-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00025896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00025896, "Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00025896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*